METTL3 and hepatocellular carcinoma: Moreover, to determine the role of m6A in sorafenib resistance in HCC, we performed rescue experiments in HCC cells with stable METTL3 depletion and sorafenib‐resistant HepG‐2 cells using wild‐type METTL3 and a catalytic mutant METTL3 (resistant to METTL3 shRNA) (Appendix Fig S2P and Q) (Fig 2E and F).